NCT03906526 2023-02-24
A Study to Evaluate Immune Biomarker Modulation in Response to VTX-2337 in Combination With an Anti- PD-1 Inhibitor in Head and Neck Cancer
Celgene
Phase 1 Terminated
Clinical Trials
10 trialsNCT02431559 2022-10-10
Phase 1/2 Study of Motolimod, Doxorubicin, and Durvalumab in Recurrent, Platinum-Resistant Ovarian Cancer
Ludwig Institute for Cancer Research
Phase 1/2 Completed
NCT04272333 2022-04-14
Intratumoral Microdosing of Motolimod in HNSCC
Presage Biosciences
Phase EARLY_PHASE1 Terminated
NCT01836029 2019-10-29
Chemotherapy Plus Cetuximab in Combination With VTX-2337 in Patients With Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck
Celgene
Phase 2 Completed
NCT02124850 2019-10-25
A Phase Ib Study of Neoadjuvant of Cetuximab Plus Motolimod and Cetuximab Plus Motolimod Plus Nivolumab
Celgene
Phase 1 Terminated
NCT00688415 2019-09-25
Safety and Pharmacologic Study of VTX-2337 in Patients With Advanced Cancer
Celgene
Phase 1 Completed
NCT01289210 2019-09-25
VTX-2337 in Combination With Radiotherapy in Patients Low-Grade B-cell Lymphomas
Celgene
Phase 1/2 Terminated
NCT02650635 2018-09-05
TLR8 Agonist VTX-2337 and Cyclophosphamide in Treating Patients With Metastatic, Persistent, Recurrent, or Progressive Solid Tumors
Mayo Clinic
Phase 1 Terminated
NCT01334177 2015-03-05
TLR8 Agonist VTX-2337 and Cetuximab in Treating Patients With Locally Advanced, Recurrent, or Metastatic Squamous Cell Cancer of Head and Neck
University of Washington
Phase 1 Completed
NCT01294293 2014-12-25
TLR8 Agonist VTX-2337 and Pegylated Liposomal Doxorubicin Hydrochloride or Paclitaxel in Treating Patients With Recurrent or Persistent Ovarian Epithelial, Fallopian Tube, or Peritoneal Cavity Cancer
GOG Foundation
Phase 1 Completed